Chirag Talati, pharma analyst at Espirito Santo Securities tells CNBC-TV18 that since the company does not generate any sales from the facility, and approval of the 18 ANDAs (Abbreviated New Drug Application) were not expected until FY13, FY12 margins will remain intact.
first published: Jul 6, 2011 02:33 pm
A collection of the most-viewed Moneycontrol videos.
